Literature DB >> 8960939

Acute effects of digitalis and enalapril on the neurohormonal profile of chagasic patients with severe congestive heart failure.

A M Khoury1, D F Davila, G Bellabarba, J H Donis, A Torres, C Lemorvan, L Hernandez, W Bishop.   

Abstract

Chagasic patients with congestive heart failure are usually treated with digitalis and converting enzyme inhibitors. According to the neurogenic and dysautonomic theories, chagasic patients would not benefit from these drugs. To clarify this controversial issue, we have studied patients with congestive heart failure and suspected Chagas' heart disease. All patients received intravenous methyl-digoxin for 24 h and oral enalapril for 96 h. Blood samples for plasma norepinephrine, aldosterone and renin were taken at baseline, after acute digitalization and following enalapril. Based on the serology for Chagas' disease, the patients were divided into non-chagasic and chagasic patients. In the chagasic group three patients were in functional class III and 3 were in functional class IV. In the non-chagasic group five patients were in functional class III and 2 were in functional class IV. Both groups had a marked and quantitatively similar degree of neurohormonal activation. All patients improved at least one functional class and lost more than 5 kg of body weight with treatment. The chagasic patients had a statistically significant reduction in plasma norepinephrine (2262 +/- 1407 to 865 +/- 390, P < 0.008, pg/ml, M +/- S.D.), plasma aldosterone (330 +/- 168 to 155 +/- 75, P < 0.01, pg/ml, M +/- S.D.) and plasma renin activity (14 +/- 13 to 2 +/- 1.6 ng/ml per h, M +/- S.D., P < 0.05), with digitalis. Following enalapril, norepinephrine and aldosterone there was a further but non-significant reduction, when compared to postdigitalis values. These results indicated that chagasic patients do benefit from digitalis and enalapril. Furthermore, the prominent and significant reduction in all three neurohormones suggest that the parasympathetic and sympathetic systems of these chagasic and non-chagasic patients, are responding to the neuromodulatory effects of digitalis and enalapril.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8960939     DOI: 10.1016/s0167-5273(96)02776-3

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

Review 1.  Chagas heart disease: report on recent developments.

Authors:  Fabiana S Machado; Linda A Jelicks; Louis V Kirchhoff; Jamshid Shirani; Fnu Nagajyothi; Shankar Mukherjee; Randin Nelson; Christina M Coyle; David C Spray; Antonio C Campos de Carvalho; Fangxia Guan; Cibele M Prado; Michael P Lisanti; Louis M Weiss; Susan P Montgomery; Herbert B Tanowitz
Journal:  Cardiol Rev       Date:  2012 Mar-Apr       Impact factor: 2.644

2.  Chagas Heart Failure in Patients from Latin America.

Authors:  Reinaldo B Bestetti
Journal:  Card Fail Rev       Date:  2016-11

3.  Emerging and under-recognized Chagas cardiomyopathy in non-endemic countries.

Authors:  Joana Cortez; Rui Providência; Evelise Ramos; Cristina Valente; Jorge Seixas; Manuela Meruje; António Leitão-Marques; António Vieira
Journal:  World J Cardiol       Date:  2012-07-26

Review 4.  Treatment of Chagas cardiomyopathy.

Authors:  Fernando A Botoni; Antonio Luiz P Ribeiro; Carolina Coimbra Marinho; Marcia Maria Oliveira Lima; Maria do Carmo Pereira Nunes; Manoel Otávio C Rocha
Journal:  Biomed Res Int       Date:  2013-11-24       Impact factor: 3.411

5.  Cardiac autonomic control mechanisms in the pathogenesis of chagas' heart disease.

Authors:  Diego F Dávila; Jose H Donis; Gabriela Arata de Bellabarba; Vanesa Villarroel; Francisco Sanchez; Lisbeth Berrueta; Siham Salmen; Barbara Das Neves
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.